Haloxen (Haloperidol)

Haloxen is prescribed for several neuropsychiatric disorders where dopamine dysregulation is implicated.

• Schizophrenia: treatment of acute and maintenance phases.
• Acute psychotic episodes associated with bipolar disorder or other conditions.
• Tourette syndrome: reduction of motor and vocal tics.
• Severe agitation or hostility in hospitalized patients.
• Off‑label use may include management of severe behavioral disturbances in dementia (when clinically justified).

Side effects of Haloxen vary in frequency and severity; patients should be aware of both common and serious reactions.

Common

• Drowsiness or sedation
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia
• Dry mouth
• Constipation
• Blurred vision
• Weight gain

Serious

• Tardive dyskinesia (involuntary movements)
• Neuroleptic malignant syndrome (fever, muscle rigidity, autonomic instability)
• Severe hypotension
• Cardiac arrhythmias (QT prolongation)
• Agranulocytosis (low white blood cell count)

Before starting Haloxen, clinicians should evaluate several safety considerations to minimize risk.

• Assess cardiovascular status, especially for QT prolongation risk.
• Review history of movement disorders or prior antipsychotic exposure.
• Monitor for signs of metabolic changes, such as weight gain or glucose intolerance.
• Use caution in patients with hepatic or renal impairment; dose adjustments may be required.
• Evaluate pregnancy and lactation status, as safety data are limited.
• Conduct regular blood counts if prolonged therapy is planned.
• Educate patients about the potential for sedation and advise against operating machinery until effects are known.

Haloxen can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Other dopamine‑blocking agents (e.g., other antipsychotics, metoclopramide) – increased risk of extrapyramidal symptoms.
• Medications that prolong QT interval (e.g., certain antiarrhythmics, macrolide antibiotics) – additive cardiac risk.
• CYP3A4 inhibitors such as ketoconazole or clarithromycin – may raise haloperidol plasma levels.

Use with caution

• CYP3A4 inducers (e.g., carbamazepine, rifampin) – may reduce effectiveness.
• CNS depressants (e.g., benzodiazepines, opioids) – enhanced sedation.
• Anticholinergic drugs – may mask extrapyramidal side effects.
• Lithium – increased risk of neurotoxicity.
• Alcohol – potentiates central nervous system effects.